O	0	2	An
B-intervention	3	11	exercise
I-intervention	12	17	trial
O	18	27	targeting
B-ethinicity	28	35	African
I-ethinicity	35	36	-
I-ethinicity	36	44	American
O	45	50	women
O	51	55	with
O	56	65	metabolic
O	66	74	syndrome
O	75	78	and
O	79	81	at
O	82	86	high
O	87	91	risk
O	92	95	for
O	96	102	breast
O	103	109	cancer
O	109	110	:
O	111	120	Rationale
O	120	121	,
O	122	128	design
O	128	129	,
O	130	133	and
O	134	141	methods
O	141	142	.

O	143	152	Metabolic
O	153	161	syndrome
O	162	165	and
O	166	173	obesity
O	174	177	are
O	178	183	known
O	184	188	risk
O	189	196	factors
O	197	200	for
O	201	207	breast
O	208	215	cancers
O	215	216	.

O	217	225	Exercise
O	226	239	interventions
O	240	243	can
O	244	255	potentially
O	256	262	modify
O	263	274	circulating
O	275	285	biomarkers
O	286	288	of
O	289	295	breast
O	296	302	cancer
O	303	307	risk
O	308	311	but
O	312	320	evidence
O	321	323	in
O	324	331	African
O	331	332	-
O	332	341	Americans
O	342	345	and
O	346	351	women
O	352	356	with
O	357	366	metabolic
O	367	375	syndrome
O	376	378	is
O	379	386	lacking
O	386	387	.

O	388	391	The
O	392	399	Focused
O	400	412	Intervention
O	413	415	on
O	416	424	Exercise
O	425	427	to
O	428	434	Reduce
O	435	441	CancEr
O	442	443	(
O	443	449	FIERCE
O	449	450	)
O	451	456	trial
O	457	459	is
O	460	461	a
O	462	473	prospective
O	473	474	,
O	475	476	6
O	476	477	-
O	477	482	month
O	482	483	,
O	484	485	3
O	485	486	-
O	486	489	arm
O	489	490	,
O	491	501	randomized
O	502	512	controlled
O	513	518	trial
O	519	521	to
O	522	529	examine
O	530	533	the
O	534	540	effect
O	541	543	of
O	544	552	exercise
O	553	555	on
O	556	563	obesity
O	563	564	,
O	565	574	metabolic
O	575	583	syndrome
O	584	594	components
O	594	595	,
O	596	599	and
O	600	606	breast
O	607	613	cancer
O	614	624	biomarkers
O	625	630	among
B-eligibility	631	638	African
I-eligibility	638	639	-
I-eligibility	639	647	American
I-eligibility	648	653	women
I-eligibility	654	656	at
I-eligibility	657	661	high
I-eligibility	662	666	risk
I-eligibility	667	669	of
I-eligibility	670	676	breast
I-eligibility	677	683	cancer
O	683	684	.

B-total-participants	685	688	Two
I-total-participants	689	696	hundred
I-total-participants	696	697	-
I-total-participants	697	702	forty
B-eligibility	703	711	inactive
I-eligibility	712	717	women
I-eligibility	718	722	with
I-eligibility	723	732	metabolic
I-eligibility	733	741	syndrome
I-eligibility	742	745	and
I-eligibility	746	754	absolute
I-eligibility	755	759	risk
I-eligibility	760	762	of
I-eligibility	763	769	breast
I-eligibility	770	776	cancer
I-eligibility	777	778	â‰¥
I-eligibility	779	780	1
I-eligibility	780	781	.
I-eligibility	781	783	40
O	784	788	will
O	789	791	be
O	792	802	randomized
O	803	805	to
O	806	809	one
O	810	812	of
O	813	816	the
O	817	822	three
O	823	828	trial
O	829	833	arms
O	833	834	:
O	835	836	1
O	836	837	)
O	838	839	a
O	840	850	supervised
O	850	851	,
O	852	860	facility
O	860	861	-
O	861	866	based
O	867	875	exercise
O	876	879	arm
O	879	880	;
O	881	882	2
O	882	883	)
O	884	885	a
O	886	890	home
O	890	891	-
O	891	896	based
O	897	905	exercise
O	906	909	arm
O	909	910	;
O	911	914	and
O	915	916	3
O	916	917	)
O	918	919	a
B-control	920	927	control
I-control	928	933	group
O	934	938	that
O	939	948	maintains
O	949	957	physical
O	958	966	activity
O	967	973	levels
O	974	981	through
O	982	985	the
O	986	992	course
O	993	995	of
O	996	999	the
O	1000	1005	trial
O	1005	1006	.

O	1007	1018	Assessments
O	1019	1023	will
O	1024	1026	be
O	1027	1036	conducted
O	1037	1039	at
O	1040	1048	baseline
O	1048	1049	,
O	1050	1051	3
O	1052	1058	months
O	1058	1059	,
O	1060	1063	and
O	1064	1065	6
O	1066	1072	months
O	1072	1073	.

O	1074	1077	The
O	1078	1085	primary
O	1086	1093	outcome
O	1094	1103	variables
O	1104	1107	are
B-outcome-Measure	1108	1122	anthropometric
I-outcome-Measure	1123	1133	indicators
I-outcome-Measure	1134	1136	of
I-outcome-Measure	1137	1144	obesity
O	1144	1145	,
B-outcome-Measure	1146	1155	metabolic
I-outcome-Measure	1156	1164	syndrome
I-outcome-Measure	1165	1175	components
O	1175	1176	,
O	1177	1180	and
B-outcome-Measure	1181	1193	inflammatory
I-outcome-Measure	1193	1194	,
I-outcome-Measure	1195	1202	insulin
I-outcome-Measure	1202	1203	-
I-outcome-Measure	1203	1210	pathway
O	1210	1211	,
O	1212	1215	and
B-outcome-Measure	1216	1224	hormonal
I-outcome-Measure	1225	1235	biomarkers
I-outcome-Measure	1236	1238	of
I-outcome-Measure	1239	1245	breast
I-outcome-Measure	1246	1252	cancer
I-outcome-Measure	1253	1257	risk
O	1257	1258	.

O	1259	1262	The
O	1263	1269	FIERCE
O	1270	1275	trial
O	1276	1280	will
O	1281	1288	provide
O	1289	1297	evidence
O	1298	1300	on
O	1301	1308	whether
O	1309	1310	a
O	1311	1316	short
O	1316	1317	-
O	1317	1321	term
O	1322	1330	exercise
O	1331	1343	intervention
O	1344	1349	might
O	1350	1352	be
O	1353	1362	effective
O	1363	1365	in
O	1366	1374	reducing
O	1375	1381	breast
O	1382	1388	cancer
O	1389	1393	risk
O	1394	1399	among
O	1400	1407	African
O	1407	1408	-
O	1408	1416	American
O	1417	1422	women
O	1423	1427	with
O	1428	1441	comorbidities
O	1442	1445	and
O	1446	1450	high
O	1451	1457	breast
O	1458	1464	cancer
O	1465	1469	risk
O	1469	1470	-
O	1470	1471	-
O	1471	1472	a
O	1473	1478	group
O	1479	1492	traditionally
O	1493	1498	under
O	1498	1499	-
O	1499	1510	represented
O	1511	1513	in
O	1514	1517	non
O	1517	1518	-
O	1518	1529	therapeutic
O	1530	1536	breast
O	1537	1543	cancer
O	1544	1550	trials
O	1550	1551	.

O	1552	1563	NCT02103140
O	1563	1564	.
